Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]

Authors Hoggatt J, Tate TA, Pelus LM

Received 22 April 2015

Accepted for publication 22 April 2015

Published 27 August 2015 Volume 2015:10(1) Pages 5421—5422


Hoggatt J, Tate TA, Pelus LM. Int J Nanomed. 2015;10:2647–2652.

In this article, Lipegfilgrastim was referred to as a "long-acting biosimilar filgrastim". The term "biosimilar" was used too broadly in this case, as Lipegfilgrastim was not approved under the biosimilar classification by the EMA. Rather, lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim.

Read the original article

Letter to the editor has been published

Creative Commons License © 2015 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.